Tuesday, 02 January 2024 12:17 GMT

Rani Therapeutics To Participate In Upcoming September Conferences


(MENAFN- GlobeNewsWire - Nasdaq) SAN JOSE, Calif., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on oral delivery of biologics, today announced that the company's management team will participate in the upcoming September conferences.

10 th Annual Best Ideas Growth (BIG10) Conference hosted by Lake Street Capital Markets
Date: Thursday, September 10, 2026
Format: 1x1 Meetings
Location: New York, NY

H.C. Wainwright 28 th Annual Global Investment Conference
Fireside Chat: Monday, September 14, 2026 at 4:00pm E.T.
Presenter: Chief Executive Officer, Talat Imran, and Chief Financial Officer, Nicholas Maestas
Format: Fireside Chat and 1x1 Meetings
Location: New York, NY

Interested parties can access the live webcast for the H.C. Wainwright conference from the Investor Relations section of the company's website at The webcast replay will be available after the conclusion of the presentation.

About Rani Therapeutics
Rani Therapeutics is a clinical-stage biotherapeutics company focused on advancing technologies to enable the development of orally administered biologics and drugs. Rani has developed the RaniPill® CapsuleTM, a novel, proprietary and patented platform technology, intended to replace subcutaneous injection or intravenous infusion of biologics and drugs with oral dosing. Rani has successfully conducted several preclinical and clinical studies to evaluate safety, tolerability and bioavailability using RaniPill® Capsule technology.

Investor Contact:
...

Media Contact:
...


MENAFN08092026004107003653ID1111635671



GlobeNewsWire - Nasdaq

Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.



More Story